Phase II begins for T-20.
D019380:Anti-HIV Agents / Q000008:administration & dosage*; D017322:Clinical Trials, Phase II as Topic; D018849:Controlled Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D000077560:Enfuvirtide; D015700:HIV Envelope Protein gp41 / Q000008:administration & dosage*; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D018579:Patient Selection; D010446:Peptide Fragments / Q000008:administration & dosage*; D014481:United States
D019380:Anti-HIV Agents; D015700:HIV Envelope Protein gp41; D010446:Peptide Fragments; D000077560:Enfuvirtide